This study discusses the results of clinical trials using cell therapy in mouse models with bone marrow- and spleen-derived endothelial progenitor cells for ischemic syndromes, concluding that transfer of bone marrow cells and EPCs may result in an increase in atherosclerotic lesion size, whereas EPC transfer could also potentially influence plaque stability.
